Introduction
============

The cytochrome P450 2C (*CYP2C*) subfamily of enzymes metabolizes \~20--30% of all pharmaceuticals in use today ([@b1-mmr-13-03-2117]). *CYP2C19* comprises 16% of the *CYP2C* subfamily ([@b2-mmr-13-03-2117]) and is involved in the metabolism of a range of clinically important compounds, including the antiplatelet therapeutic agent clopidogrel; anticonvulsants such as phenytoin and diazepam; proton pump inhibitors such as omeprazole and lansoprazole; tricyclic antidepressants such as amitriptyline and clomipramine; and the selective serotonin reuptake inhibitor citalopram ([@b3-mmr-13-03-2117]--[@b7-mmr-13-03-2117]).

An association has been identified between *CYP2C19* genetic variation and therapeutic outcomes, adverse drug reactions and treatment failures ([@b8-mmr-13-03-2117]). Among the various characterized polymorphic variants of *CYP2C19*, the most common loss of function mutations are *CYP2C19*^\*^2 (681G\>A, rs4244285) and *CYP2C19*^\*^3 (636G\>A, rs4986893) ([@b9-mmr-13-03-2117]). By contrast, the common *CYP2C19*^\*^17 allele (-806CNT, rs12248560) has been associated with increased gene expression and enzyme activity ([@b9-mmr-13-03-2117]). *CYP2C19* exhibits genetic polymorphisms among different races, as demonstrated by variations in the metabolism of therapeutic agents ([@b10-mmr-13-03-2117]). A previous study evaluated enzymatic activity and genotypic association of *CYP2C19* among Chinese, Korean, Japanese and Caucasian populations ([@b11-mmr-13-03-2117]).

Tibet is one of the oldest ethnic groups in China, with their own spoken and written language. To the best of our knowledge, no genotypic information on *CYP2C19* mutants in this population is currently available. The aim of the present study was to determine *CYP2C19* mutant allele and genotype frequencies in a healthy Tibetan population. The results were compared with *CYP2C19* genetic polymorphisms in other populations. The results of the present study may assist in predicting adverse effects and optimization of dosage and treatment with medications metabolized by CYP2C19 in the Tibetan population.

Materials and methods
=====================

Participants
------------

A group of 96 normal, healthy, non-related Tibetans (including 48 males and 48 females) were recruited between October and December 2009 from Xizang Minzu University in Xianyang. All participants were Tibetan Chinese living in the Tibet Autonomous Region of China, with a minimum of three generations of paternal ancestry within this ethnic group. Subjects with any type of medical illness, organ transplant, drug/alcohol addiction or those who were pregnant were excluded from the study. These exclusion criteria were used to minimize factors that may have influenced genetic variation in the genes of interest.

The present study was approved by The Human Research Committee of the Xizang Minzu University for Approval of Research Involving Human Subjects; all subjects were informed, verbally and in writing, about the experimental procedures, confidentiality and the purpose of the study. All participants gave their written informed consent prior to enrollment in the study.

Genotyping of CYP2C19
---------------------

A blood sample (5 ml) was taken from each subject in an EDTA tube (Jiangsu Kangjie Medical Devices Co., Ltd. Jiangyan, China) and DNA was extracted using the GoldMag-Mini Whole Blood Genomic DNA Purification kit (GoldMag Co., Ltd., Hainan, China), according to the manufacturer\'s instructions. Primers (presented in [Table I](#tI-mmr-13-03-2117){ref-type="table"}; Sangon Biotech, Shanghai, China) were designed to amplify the 5′-flanking regions, all exons, and all introns of the *CYP2C19* gene. Polymerase chain reaction (PCR) was performed for all single nucleotide polymorphisms (SNPs) in 10 *µ*l reactions with 1 *µ*l template DNA, 5 *µ*l HotStar Taq Master mix (Qiagen, Germantown, MD, USA), 0.5 *µ*l each primer (5 *µ*M) and 3 *µ*l deionized water. The thermal cycling conditions were as follows: Denaturation step of 15 min at 95°C; followed by 35 cycles of denaturation at 95°C for 30 sec, 55--64°C for 30 sec and 72°C for 1 min; and a final extension step at 72°C for 3 min. PCR products were incubated with 0.5 *µ*l shrimp alkaline phosphatase (Roche Diagnostics, Basel, Switzerland), 8 *µ*l HotStar PCR product, and 1.5 *µ*l deionized water (to a total volume of 10 *µ*l), at 37°C for 30 min, followed by heat inactivation at 80°C for 15 min. Purified PCR products were sequenced directly using the ABI Prism BigDye Terminator Cycle Sequencing kit version 3.1 (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), using an ABI Prism 3100 sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.).

Statistical analysis
--------------------

Sequencher 4.10.1 (<http://www.genecodes.com/>) software was used to analyze the sequences, including manual curation, fragment assembly and mutation detection. *CYP2C19* variants were designed based on the nucleotide reference sequence NG_008384.2, which is searched from the National Center for Biotechnology Information database (NCBI database, <http://www.ncbi.nlm.nih.gov/>). The *CYP* allele nomenclature is quoted from the Human Cytochrome P450 Allele Nomenclature Committee tables (<http://www.cypalleles.ki.se/>). The χ^2^ test was used to compare allele and genotype frequencies, with descriptive analysis used to compare allele frequencies between the Tibetan and other populations ([@b12-mmr-13-03-2117]). Haploview 4.1 (<http://broad.mit.edu/mpg/haploview>) was used to assess linkage disequilibrium (LD) and Hardy-Weinberg equilibrium for each genetic variant ([@b13-mmr-13-03-2117]). Haplotypes were constructed from the selected tag SNPs and haplotype frequencies were derived for the Tibetan population.

Translational prediction
------------------------

Non-synonymous SNPs in the *CYP2C19* coding regions were analyzed to predict the coded protein function. Two algorithms, Sorting Intolerant From Tolerant (SIFT; <http://sift.bii.a-star.edu.sg/>) and Polymorphism Phenotyping version 2 (PolyPhen-2; <http://genetics.bwh.harvard.edu/pph2/>), were used to perform the functional prediction of non-synonymous SNPs ([@b14-mmr-13-03-2117]). Depending on the metabolic activity of *CYP2C19*, the subjects were divided into three phenotypic groups: Poor metabolizer (PM), extensive metabolizer and ultra-rapid metabolizer, based on CYP allele nomenclature (<http://www.cypalleles.ki.se/>) ([@b15-mmr-13-03-2117]).

Results
=======

Genetic variants
----------------

*CYP2C19* was sequenced in the group of 96 Tibetan participants (48 males and 48 females) and the results successfully identified a total of 27 *CYP2C19* polymorphisms in this population. Three of the polymorphisms had not previously been reported in either the National Center for Biotechnology Information database or the Human Cytochrome P450 Allele Nomenclature Committee tables ([Table II](#tII-mmr-13-03-2117){ref-type="table"}), two of the novel polymorphisms were synonymous mutations within exon five and one was a non-synonymous mutation in exon eight. No duplications or deletions within the sequenced *CYP* genes were observed.

Allele and genotype frequency
-----------------------------

A total of five *CYP2C19* alleles were detected in the Tibetan study population ([Table III](#tIII-mmr-13-03-2117){ref-type="table"}). The *CYP2C19*^\*^1A allele had the highest frequency (50%), followed by the *CYP2C19*^\*^1B allele (28.13%) and the *CYP2C19*^\*^2A allele (15.10%). The other two identified alleles, *CYP2C19*^\*^3A and ^\*^17, were relatively rare with frequencies of 5.21% and 1.56%, respectively. These results indicate that alleles that do not affect the function of *CYP2C19* (*CYP2C19*^\*^1A and ^\*^1B), are the most prevalent with a combined frequency of 68.13%, followed by alleles that inactivate enzyme function (*CYP2C19*^\*^2A and ^\*^3A) with a combined frequency of 20.31%. The *CYP2C19*^\*^17 allele, which may increase the activity of *CYP2C19*, had the lowest frequency of 1.56%.

Four *CYP2C19* genotypes were identified, with frequencies ranging from 3.13 to 56.25% in the Tibetan population under study ([Table III](#tIII-mmr-13-03-2117){ref-type="table"}). Of the identified genotypes, one exhibits normal enzymatic activity, two exhibit reduced enzymatic activity and one exhibits increased enzymatic activity. The *CYP2C19* allele frequencies were further compared with previously published data from different countries and ethnic groups in Eastern Asia ([@b16-mmr-13-03-2117]--[@b19-mmr-13-03-2117]), Southern Asia ([@b20-mmr-13-03-2117]), Europe ([@b21-mmr-13-03-2117]--[@b25-mmr-13-03-2117]) and Africa ([@b26-mmr-13-03-2117]--[@b28-mmr-13-03-2117]) ([Table IV](#tIV-mmr-13-03-2117){ref-type="table"}). The results of the present study demonstrated that the frequency of the wild-type allele, *CYP2C19*^\*^1, in the Tibetan group was significantly lower than in Caucasian populations (P\<0.05), however was highest in Asian populations. Furthermore, the frequencies of *CYP2C19*^\*^2 and *CYP2C19*^\*^3 were significantly higher (P\<0.05) among those of Tibetan descent compared with Caucasian and African populations.

LD analysis
-----------

LD analysis was performed using Haploview with confidence intervals to define LD blocks ([Fig. 1](#f1-mmr-13-03-2117){ref-type="fig"}). The LD was determined for *CYP2C19* using those SNPs whose minor allele frequencies were \>0.05, as SNPs with low frequency have little power to detect LD. The deviation from the expected (D\') was calculated, in addition to the correlation of alleles at two loci (r^2^) and the LD statistic for all possible pairs of SNPs. Two LD blocks across *CYP2C19* were identified. Block 1, the larger of the two blocks, spans a 61 kb region from nucleotide 19154 (rs4244285) in the promoter region to nucleotide 80160 (rs3758580). Block 2 includes five tightly clustered SNPs (rs4917623, rs17886522, 2C19_87331, rs17882572 and rs17885052), each with a D\' value equal to 1 (indicating complete LD).

Protein function prediction
---------------------------

Three novel *CYP2C19* variants were identified with only one of these being a non-synonymous mutation. SIFT was used to predict the effect of mutations on CYPC219 function, with the Ala423Lys substitution predicted to affect protein function with a score of 0.01 (results are divided into four levels: Intolerant, 0.00--0.05; potentially intolerant, 0.051--0.10; borderline, 0.101--0.2; tolerant, 0.201--1.00). By contrast, PolyPhen-2 analysis predicted that this mutation is benign with a score of 0.005 ([Fig. 2](#f2-mmr-13-03-2117){ref-type="fig"}, the results here were divided into five levels: Benign, 0.000--0.999; borderline, 1.000--1.249; potentially damaging, 1.250--1.499; possibly damaging, 1.500--1.999; probably damaging, \>2.000; and when the closer the score is to zero, the less damage is predicted).

Discussion
==========

The polymorphic isoenzyme *CYP2C19* is responsible for the metabolism of various important therapeutic agents and *CYP2C19* polymorphisms result in inter-individual and inter-ethnic variation in the break-down of multiple therapeutic agents ([@b29-mmr-13-03-2117]). To the best of our knowledge, the present study is the first to systematically screen a group of Tibetan individuals for *CYP2C19* variants by direct sequencing and compare these results with ethnic populations from different continents. The present study observed 27 genetic variants, including three novel polymorphisms, five alleles and four genotypes. Only one of the novel genetic variants, within exon eight, was a non-synonymous mutation.

The frequency of the wild-type *CYP2C19* allele (*CYP2C19*^\*^1) in the Tibetan study population was notably lower than in Caucasian populations, which was consistent with findings in a previous study on the Chinese Han population ([@b30-mmr-13-03-2117]). A previous study has demonstrated that *CYP2C19*^\*^2 and *CYP2C19*^\*^3 are null alleles, which result in the total absence of enzyme activity and these two alleles account for \>99% of oriental PMs and \~87% of Caucasian PMs ([@b31-mmr-13-03-2117]). The occurrence of *CYP2C19*^\*^3 in the Tibetan subjects in the present study was significantly higher (P\<0.01) than the frequency reported for Caucasian and African populations. These results suggest that the toxicological or pharmacological properties of medications that are metabolized by *CYP2C19* are likely to differ among Tibetans, other Asians, Caucasian and African populations. *CYP2C19*^\*^17 is within the promoter region of *CYP2C19* and this mutation is frequently reported in oriental races ([@b16-mmr-13-03-2117],[@b30-mmr-13-03-2117],[@b32-mmr-13-03-2117]). Amongst the Tibetan study population *CYP2C19*^\*^17 had a frequency of 1.56%, which is not significantly different compared with a previous study on the Chinese Han population ([@b30-mmr-13-03-2117]).

Various clinically important therapeutic agents are substrates for *CYP2C19*, as outlined earlier. As different mutant alleles are associated with different phenotypes and enzyme activities, *CYP2C19* genotypic and phenotypic analysis may be used to optimize dosages, improve treatment efficacy and optimize the cost effectiveness of certain treatments ([@b33-mmr-13-03-2117]). Clopidogrel is an inactive prodrug that requires hepatic bioactivation via *CYP2C19* to exert its effects ([@b34-mmr-13-03-2117]). This process is impaired in PMs, such as individuals with the *CYP2C19*^\*^2 allele and, consequently, the production of the active metabolite in these individuals is reduced ([@b35-mmr-13-03-2117]). The frequency value of *CYP2C19*^\*^2 in the present Tibetan study population was between that of the other Asian groups and Caucasians, thus, it may be recommended that the dosage of clopidogrel should also lie between those used for the two populations.

An analysis of novel genetic variants in the coding region demonstrated only one non-synonymous mutation, which results in an amino acid change from asparagine to lysine. The results of the protein function analysis were determined to be intolerant and benign by SIFT and PolyPhen-2, respectively. The prediction accuracy of SIFT and PolyPhen-2 is 63 and 75%, while the false positive rate is 19 and 9%, respectively ([@b14-mmr-13-03-2117],[@b36-mmr-13-03-2117]). The novel genetic variants identified in the present study should be further elucidated by other means in future studies.

In conclusion, results from the present study provide a basic profile of *CYP2C19* in the Tibetan population, and may be used to determine optimal dosage recommendations, leading to individualized medicine.
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###### 

Primers and amplicon sizes for cytochrome P450 2C19.

  Primer     Primer sequence (5′→3′)        Polymerase chain reaction product size (bp)
  ---------- ------------------------------ ---------------------------------------------
  Promoter   F: GCCTGTTTTATGAACAGGATGA      918
  Promoter   R: TAAGACAACCGTGAGCTTGC        
  Exon1      F: ACAGAGTGGGCACTGGGACGA       844
  Exon1      R: GGTCCTAAACCCACAGCTGCTTCC    
  Exon2_3    F: TTGTCTGACCATTGCCTTGA        833
  Exon2_3    R: TCTCAGCTTCAAACCCTGCT        
  Exon4      F: CCCCAACTATTCTCACCCTTT       916
  Exon4      R: AAAGTGTGAATTGAAGGACAAGC     
  Exon5      F: TCAGGTTGTGCAAACTCTTTT       908
  Exon5      R: CCTTCACTCACTTTTTGATGGA      
  Exon6      F: ATGTTGGTAAGTATACAATGTGAGT   386
  Exon6      R: TCACACCATTAAATTGGGACAGA     
  Exon7      F: TTTTGATTGGAAATTTTAGTCCATT   921
  Exon7      R: TCAGTTCTTTCCAAACTGACCT      
  Exon8      F: GTCACTGGCCTTAAGCTCATGCCT    718
  Exon8      R: CCCAGCCTAGGGGGTGAGGG        
  Exon9      F: TGAGAGTAGGGGAGGTGAAGA       907
  Exon9      R: GATGACGGGTCAGAAGAAGC        
  3′-UTR     F: ACGGATTTGTGTGGGAGAGGGC      674
  3′-UTR     R: AATGCTCAGCCAAAATAGCTTCCCT   

bp, base pairs; UTR, untranslated region.

###### 

Positions and frequencies of cytochrome P450 2C19 genetic variants in the Tibetan study population.

  No.   SNP           Position   Region     Nucleotide change   Allele            Frequency   Percentage (%)   Amino-acid effect
  ----- ------------- ---------- ---------- ------------------- ----------------- ----------- ---------------- ---------------------------------------------------------
  1     rs576566073   −844       Promoter   G\>T                                  1/96        1.042            Not translated
  2     rs12248560    −806       Promoter   C\>T                *CYP2C19^\*^17*   3/96        3.125            Not translated
  3     /             −643       Promoter   C\>T                                  1/96        1.042            Not translated
  4     /             −597       Promoter   A\>G                                  1/96        1.042            Not translated
  5     rs17885098    99         Exon 1     C\>T                                  86/96       89.583           Pro33[a](#tfn2-mmr-13-03-2117){ref-type="table-fn"}
  6     /             483        Intron 1   G\>A                                  1/96        1.042            Not translated
  7     rs7918461     527        Intron 1   A\>T                                  3/96        3.125            Not translated
  8     rs4986893     17948      Exon 4     G\>A                *CYP2C19^\*^3A*   11/86       12.644           Trp212Ter
  9     rs7088784     18911      Intron 4   A\>G                                  22/96       22.917           Not translated
  10    rs4244285     19154      Exon 5     G\>A                *CYP2C19^\*^2A*   39/96       40.625           Pro227[a](#tfn2-mmr-13-03-2117){ref-type="table-fn"}
  11                  19184      Exon 5     T\>C                Novel 1           1/96        1.042            Leu237[a](#tfn2-mmr-13-03-2117){ref-type="table-fn"}
  12                  19280      Exon 5     C\>A                Novel 2           1/96        1.042            IlE269[a](#tfn2-mmr-13-03-2117){ref-type="table-fn"}
  13    rs12571421    19520      Intron 5   A\>G                                  39/96       40.625           Not translated
  14    rs557466494   58017      Intron 6   G\>A                                  1/96        1.042            Not translated
  15    rs28399513    79936      Intron 6   T\>A                                  37/94       39.362           Not translated
  16    rs374366253   79980      Intron 6   T\>C                                  1/94        1.064            Not translated
  17    rs3758580     80160      Exon 7     C\>T                *CYP2C19^\*^2A*   37/94       39.362           Val330[a](#tfn2-mmr-13-03-2117){ref-type="table-fn"}
  18    rs3758581     80161      Exon 7     A\>G                                  93/94       98.936           Ile331Val[b](#tfn3-mmr-13-03-2117){ref-type="table-fn"}
  19    rs4917623     87106      Intron 7   T\>C                                  79/96       82.292           Not translated
  20    rs17886522    87313      Exon 8     A\>C                *CYP2C19^\*^3A*   12/96       12.500           Gly417[a](#tfn2-mmr-13-03-2117){ref-type="table-fn"}
  21                  87331      Exon 8     C\>A                Novel 3           2/96        2.083            Asn423Lys[b](#tfn3-mmr-13-03-2117){ref-type="table-fn"}
  22    rs17882572    87594      Intron 8   G\>T                                  13/96       12.500           Not translated
  23    rs17885052    87620      Intron 8   A\>T                                  22/96       22.917           Not translated
  24    rs12268020    89909      Intron 8   C\>T                                  3/96        3.125            Not translated
  25    /             90302      3′-UTR     C\>T                                  1/96        1.042            Not translated
  26    /             90325      3′-UTR     C\>T                                  2/96        2.083            Not translated
  27    rs185030154   90581      3′-UTR     T\>C                                  3/96        3.125            Not translated

Synonymous mutations.

Non-synonymous mutations. UTR, untranslated region; SNP, single nucleotide polymorphism.

###### 

Allele and genotype frequencies of *CYP2C19* in the Tibetan study population.

  A, Allele frequencies                    
  ----------------------- ---- ----------- -------
  ^\*^1A                  96   Normal      50
  ^\*^1B                  54   Normal      28.13
  ^\*^2A                  29   None        15.10
  ^\*^3A                  10   None        5.21
  ^\*^17                  3    Increased   1.56

  B, Genotype frequencies                                     
  ------------------------- ---- ---------------------------- -------
  ^\*^1A/^\*^1B             54   Normal enzyme activity       56.25
  ^\*^1A/^\*^2A             29   Reduced enzymatic activity   30.21
  ^\*^1A/^\*^3A             10   Reduced enzymatic activity   10.42
  ^\*^1A/17                 3    Increased enzyme activity    3.13

*CYP2C19*, cytochrome P450 2C19.

###### 

*CYP2C19* allele frequencies in different populations.

  Population           n     Allele frequency (%)                                  Ref.                                                                                                                      
  -------------------- ----- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------ ------ -------------------------
  Asian subjects                                                                                                                                                                                             
   Tibetan             96    78.13                                                 15.10                                                 5.21                                                  /      1.56   Present
   Chinese Han         100   67.50                                                 25.50                                                 2.00                                                  0.50   3.00   ([@b16-mmr-13-03-2117])
   Chinese Dai         193   66.30[a](#tfn5-mmr-13-03-2117){ref-type="table-fn"}   30.30[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   3.40                                                  /      /      ([@b17-mmr-13-03-2117])
   Japanese            140   53.90[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   35.00[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   11.10                                                 /      /      ([@b18-mmr-13-03-2117])
   Korean              103   67.00                                                 21.00                                                 12.00                                                 /      /      ([@b19-mmr-13-03-2117])
   Vietnamese          90    62.00[a](#tfn5-mmr-13-03-2117){ref-type="table-fn"}   24.00                                                 14.00[a](#tfn5-mmr-13-03-2117){ref-type="table-fn"}   /      /      ([@b20-mmr-13-03-2117])
   Thai                121   59.90[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   35.10[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   5.00                                                  /      /      ([@b20-mmr-13-03-2117])
  Caucasian subjects                                                                                                                                                                                         
   Swedish             175   76.60                                                 23.10                                                 0.30[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b21-mmr-13-03-2117])
   Russian             290   88.30[a](#tfn5-mmr-13-03-2117){ref-type="table-fn"}   11.40                                                 0.30[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b22-mmr-13-03-2117])
   Italian             360   88.90[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   11.10                                                 0.00[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b23-mmr-13-03-2117])
   Bolivian            778   92.10[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   7.80[a](#tfn5-mmr-13-03-2117){ref-type="table-fn"}    0.10[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b24-mmr-13-03-2117])
   Faroese             312   97.10[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}   2.90[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    0.00[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b25-mmr-13-03-2117])
  African subjects                                                                                                                                                                                           
   Tanzanian           251   81.50                                                 17.90                                                 0.60[b](#tfn6-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b26-mmr-13-03-2117])
   Ethiopian           114   84.00                                                 14.00                                                 2.00                                                  /      /      ([@b27-mmr-13-03-2117])
   Zimbabwean          84    86.90                                                 13.10                                                 0.00[a](#tfn5-mmr-13-03-2117){ref-type="table-fn"}    /      /      ([@b28-mmr-13-03-2117])

P\<0.01, compared with the data of the present study;

P\<0.05, compared with the data of the present study. / indicates synonymous SNP mutations that have no effects on protein sequences. *CYP2C19*, cytochrome P450 2C19.
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